Abstract
Introduction. Chronic viral hepatitis C is an infectious disease that is widespread among the working-age population and is often diagnosed at liver cirrhosis stage. The opportunity to slow down the progress of infection and subsequent complications appeared when the drugs with direct antiviral action became wildly available. However, the problem of antiviral treatment decompensated liver cirrhosis patients (Child-Pugh classes B and C) is still controversial and discussed. This category of patients is still the most difficult to treat. Research objectives. Search for a comprehension of the optimal liver function for the safe administration of DAA, determination of the optimal timing and DAA regimen for patients with decompensated cirrhosis based on a review of the literature. Methods. The source of information was PubMed medical bibliographic databases, from which 26 original articles for 2015–2021 were selected. Conclusion. Relatively small number of patients with cirrhosis Child-Pugh C, the high incidence of adverse events and decompensations, and the absence of clearly defined criteria for prescribing DAA, this problem requires further study and research.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call